From Pandemic Powerhouse to Cancer Crusader: BioNTech’s Bold Leap Forward
BioNTech is undergoing a transformative phase with a notable revenue contraction in Q4 2024, though it exceeded market expectations. Despite a sharp decline in profit, BioNTech’s earnings per share surpassed…